AstraZeneca opens $1B Kendall Square R&D site amid China dealmaking wave
- AstraZeneca opened a new R&D site in Boston's Kendall Square, marking a $1 billion investment.
- STAT frames the opening against a backdrop of heavy dealmaking with Chinese biotechs and uncertainty in the US biotech hub.
- Only the public STAT+ summary was available; site scope and headcount are not verified.
💡 Points
Planting a $1B flag in Kendall Square while licensing heavily from China looks like hedging: keep US discovery talent close even as external innovation shifts east. It's a capex signal, not a pipeline one, so the tell is whether the site hosts internal discovery or mostly integrates in-licensed assets.